Article CommentaryCommentary

Sterility Assurance—Current and Future State

Edward C. Tidswell, James P. Agalloco and Radha Tirumalai
PDA Journal of Pharmaceutical Science and Technology May 2022, 76 (3) 263-277; DOI: https://doi.org/10.5731/pdajpst.2020.012526

References

  1. 1.↵
    U.S. Pharmacopeial Convention, General Chapter <1211> Sterility Assurance. In USP 41—NF 36 Supplement 2, USP: Rockville, MD, 2018.
  2. 2.↵
    1. Sandle T.,
    2. Tidswell E. C.
    1. Hussong D.
    History of Sterile Products and Regulation. In Aseptic and Sterile Processing: Control, Compliance, and Future Trends; Sandle T., Tidswell E. C., Eds.; DHI Publishing: River Grove, IL, 2017; pp 99–116.
  3. 3.↵
    General Medical Council. Tests for Sterility. In British Pharmacopoeia, 1932; pp 632–633.
  4. 4.↵
    1. Bathgate H.,
    2. Lazarri D.,
    3. Cameron H.,
    4. McKay D.
    The Incubation Period in Sterility Testing. J. Parenter. Sci. Technol. 1993, 47 (5), 254–257.
    OpenUrlPubMed
  5. 5.↵
    1. Moldenhauer J.,
    2. Sutton S. V. W.
    Towards an Improved Sterility Test. PDA J. Pharm. Sci. Technol. 2004, 58 (6), 284–286.
    OpenUrlFREE Full Text
  6. 6.↵
    U.S. Pharmacopeial Convention, General Chapter <71> Sterility Tests. In USP 41—NF 36 Supplement 2, USP: Rockville, MD, 2018.
  7. 7.↵
    U.S. Pharmacopeial Convention, General Chapter <1222> Terminally Sterilized Pharmaceutical Products—Parametric Release. In USP 27—NF 22 Supplement 1, USP: Rockville, MD, 2004.
  8. 8.↵
    1. Eglovitch J.
    USP Sparks Debate over Rapid Sterility Testing for Cell and Gene Therapies. Pink Sheet 2018, 80 (44), 16–18.
    OpenUrl
  9. 9.↵
    1. Barrett D. M.,
    2. Singh N.,
    3. Porter D. L.,
    4. Grupp S. A.,
    5. June C. H.
    Chimeric Antigen Receptor Therapy for Cancer. Annu. Rev. Med. 2014, 65 (1), 333–347. 2014,
    OpenUrlCrossRefPubMed
  10. 10.↵
    European Medicines Agency, Guideline on the Sterilization of the Medicinal Product, Active Substance, Excipient and Primary Container (Draft). EMA: London, 2016.
  11. 11.↵
    USP <1071> Rapid Sterility Testing of Short-Life Products—A Risk Based Approach. Pharmacopeial Forum 2018, 44 (5).
  12. 12.↵
    1. Cundell A. M.
    Microbial Ecology of the Human Skin. Microb. Ecol. 2018, 76 (1), 113–120.
    OpenUrl
  13. 13.↵
    1. Drennan M. R.
    What is “Sterile Blood”. Br. Med. J 1942, 2 (4269), 526.
    OpenUrlFREE Full Text
  14. 14.↵
    1. Hayes R. J.
    Cost of Quality (CoQ)—An Analysis of the Cost of Maintaining a State of Compliance. Int. Pharm. Ind. 2014, 6 (1), 74–76.
    OpenUrl
  15. 15.↵
    U.S. Food and Drug Administration, 21 CFR Part 211.165(b). U.S. Department of Health and Human Services. Government Publishing Office: Washington, DC.
  16. 16.↵
    U.S. Food and Drug Administration, 21 CFR Part 200.50 and 51. U.S. Department of Health and Human Services. Government Publishing Office: Washington, DC.
  17. 17.↵
    U.S. Food and Drug Administration, 21 CFR Part 211.165(a). U.S. Department of Health and Human Services. Government Publishing Office: Washington, DC.
  18. 18.↵
    U.S. Food and Drug Administration, 21 CFR Part 211. 167(a). U.S. Department of Health and Human Services. Government Publishing Office: Washington, DC.
  19. 19.↵
    U.S. Food and Drug Administration, Guidance for Industry: Submission of Documentation of Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2010.
  20. 20.↵
    U.S. Food and Drug Administration, 21 CFR Part 212—Current Good Manufacturing Practice for Positron Emission Tomography Drugs. U.S. Department of Health and Human Services. Government Publishing Office: Washington, DC.
  21. 21.↵
    U.S. Food and Drug Administration, 21 CFR Part 800—Medical Devices—Current Good Manufacturing Practice (CGMP). U.S. Department of Health and Human Services. Government Publishing Office: Washington, DC.
  22. 22.↵
    1. Stevens-Riley M.
    Parametric Release: A Regulatory Perspective. Am. Pharm. Rev 2015, 18 (3).
  23. 23.↵
    1. Tirumalai R.,
    2. Porter D.
    Terminal Sterilization and Potential for Parametric Release. Am. Pharm. Rev 2005, 8 (4), 26–36.
    OpenUrl
  24. 24.↵
    1. Sandle T.,
    2. Tidswell E. C.
    1. Tidswell E. C.,
    2. Bennett S. E.
    Sterility. In Aseptic and Sterile Processing: Control, Compliance, and Future Trends; Sandle T., Tidswell E. C., Eds.; DHI Publishing: River Grove, IL, 2017, pp 17–50.
  25. 25.↵
    1. Vartoukian S. R.,
    2. Palmer R. M.,
    3. Wade W. G.
    Strategies for Culture of ‘Unculturable’ Bacteria. FEMS Microbiol. Lett. 2010, 309 (1), 1–7.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Epstein S. S.
    The Phenomenon of Microbial Uncultivability. Curr. Opin. Microbiol. 2013, 16 (5), 636–642.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Norris J. R.,
    2. Ribbons D. W.
    1. Postgate J. R.
    Viable Counts and Viability. Methods in Microbiology, Norris J. R., Ribbons D. W., Eds.; Academic Press: New York, 1969; Vol. 1, pp 611–628.
    OpenUrl
  28. 28.↵
    1. Barer M. R.,
    2. Harwood C. R.
    Bacterial Viability and Culturability. Adv. Microb. Physiol. 1999, 41, 93–137.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Kell D. B.,
    2. Young M.
    Bacterial Dormancy and Culturability: The Role of Autocrine Growth Factors: Commentary. Cur. Opin. Microbiol. 2000, 3 (3), 238–243.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Odlaug T. E.,
    2. Ocwieja D. A.,
    3. Purohit K. S.,
    4. Riley R. M.,
    5. Young W. E.
    Sterility Assurance for Terminally Sterilized Products without End Product Sterility Testing. J. Parenter. Sci. Technol. 1984, 38 (4), 141–147.
    OpenUrlPubMed
  31. 31.↵
    1. Mollah A. H.,
    2. Long M.,
    3. Baseman H. S.
    1. Tidswell E. C.
    Aseptic Processing: Two. In Risk Management: Applications in Pharmaceutical and Biopharmaceutical Manufacturing; Mollah A. H., Long M., Baseman H. S., Eds.; Wiley: Hoboken, NJ, 2013; pp 243–274.
  32. 32.↵
    U.S. Pharmacopeial Convention, General Chapter <1116> Microbiological Control and Monitoring of Aseptic Processing Environments, In USP 29—NF 24, USP: Rockville, MD, 2010
  33. 33.↵
    Pharmaceutical Quality Research Institute. PQRI Aseptic Processing Working Group—Final Report—2002. www.pqri.org/wp-content/uploads/2015/12/finalreport.pdf (accessed February 16, 2022).
  34. 34.↵
    Parenteral Drug Association Inc, 2017 PDA Aseptic Processing Survey; Bethesda, MA, 2017.
  35. 35.↵
    1. Agalloco J.,
    2. Akers J.
    The Myth Called Sterility. Pharm. Technol. 2010, 34 (3 Suppl), S44–S45, Continued online at Pharmtech.com.
    OpenUrl
  36. 36.↵
    U.S. Food and Drug Administration, Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2004.
  37. 37.↵
    European Medicines Agency, Annex 1: Manufacture of Sterile Medicinal Products (draft revision). EMA: London, 2020.
  38. 38.↵
    U.S. Pharmacopeial Convention, General Chapter <1211> Sterilization and Sterility Assurance of Compendial Articles. In USP 21—NF 16, USP: Rockville, MD, 1985, pp. 1347-1352.
  39. 39.↵
    U.S. Pharmacopeial Convention, General Chapter <1229> Sterilization of Compendial Articles. In USP 29—NF 34, USP: Rockville, MD, 2013.
  40. 40.↵
    European Medicines Agency, Guideline on the Sterilisation of the Medicinal Product, Active Substance, Excipient and Primary Container. EMA: London, 2019.
  41. 41.↵
    1. Agalloco J. P.
    Kill the Bioburden, Not the Biological Indicator. BioPharm Int. 2017, 30 (4), 50–52.
    OpenUrl
  42. 42.↵
    1. Bigelow W. D.
    The Logarithmic Nature of Thermal Death Time Curves. J. Infec. Dis 1921, 29 (5), 528–536.
    OpenUrlCrossRef
  43. 43.↵
    1. Block S. S.
    1. Pflug I. J.,
    2. Holcomb R. G.
    Principles of the Thermal Destruction of Microorganisms. In Disinfection, Sterilization, and Preservation, 4th ed.; Block S. S., Ed.; Lea & Febiger: Philadelphia, PA, 1991; pp 85–128.
  44. 44.↵
    1. Russell A. D.,
    2. Hugo W. B.,
    3. Ayliffe G. A. J.
    1. Russell A. D.
    Destruction of Bacterial Spores by Thermal Methods. In Principles and Practice of Disinfection, Preservation and Sterilization, 3rd ed.; Russell A. D., Hugo W. B., Ayliffe G. A. J., Eds.; Blackwell Science: Oxford, 1999; pp 640–656.
  45. 45.↵
    1. Russell A. D.,
    2. Hugo W. B.,
    3. Ayliffe G. A. J.
    1. Gould G. W.
    New and Emerging Technologies. In Principles and Practice of Disinfection, Preservation and Sterilization, 3rd ed.; Russell A. D., Hugo W. B., Ayliffe G. A. J., Eds.; Blackwell Science: Oxford, 1999; pp 767–776.
  46. 46.↵
    1. Lingnau J.
    Standard versus Non-Standard Sterilization Processes. Pharm. Ind. 1991, 53, 771–775.
    OpenUrl
  47. 47.↵
    International Organization for Standardization, ISO 11137–1: 2006 Sterilization of Health Care Products—Radiation—Part 1: Requirements for Development, Validation and Routine Control of a Sterilization Process for Medical Device. ISO: Geneva, 2006.
  48. 48.↵
    1. Timmins J.,
    2. Moe E.
    A Decade of Biochemical and Structural Studies of the DNA Repair Machinery of Deinococcus radiodurans: Major Findings, Functional and Mechanistic Insight and Challenges. Comput. Struct. Biotechnol. J. 2016, 14, 168–176.
    OpenUrlCrossRef
  49. 49.↵
    1. Richter S. G.,
    2. Barnard J.
    The Radiation Resistance of Ascospores and Sclerotia of Pyronema domesticum. J. Ind. Microbiol. Biotechnol. 2002, 29 (2), 51–54.
    OpenUrlPubMed
  50. 50.↵
    1. Agalloco J. P.,
    2. Akers J.,
    3. Madsen R.
    What is Advanced Aseptic Processing? Pharma Manuf. 2006, 4 (2), 25–27.
    OpenUrl
  51. 51.↵
    1. Tidswell E. C.,
    2. McGarvey B.
    Quantitative Risk Modeling in Aseptic Manufacture. PDA J. Pharm. Sci. Technol. 2006, 60 (5), 267–283.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    1. Tidswell E. C.,
    2. McGarvey B.
    Quantitative Risk Modeling Assists Parenteral Batch Disposition. Eur. J. Parenter. Pharm. Sci. 2007, 12 (2), 51–57.
    OpenUrl
  53. 53.↵
    1. Morrissey R. F.,
    2. Bruch C. W.,
    3. Sharbaugh R. J.,
    4. Favero M. S.,
    5. Jarvis W. R.,
    6. Masefield J.
    Sterility and Safety Assurance of Medical Devices. Medical Device and Diagnostic Industry 1992, 115, 78–81.
    OpenUrl
  54. 54.↵
    1. Mosely G. A.
    Sterility Assurance Level (SAL)—The Term and Its Definition Continues to Cause Confusion in the Industry. PMF Newsletter 2008, 14 (5), 2–14.
    OpenUrl
  55. 55.↵
    1. von Woedtke T.,
    2. Kramer A.
    The Limits of Sterility Assurance. GMS Krankenhhyge. Interdiszip. 2008, 3 (3), 1–10.
    OpenUrl
  56. 56.↵
    1. Agalloco J.,
    2. Tidswell E. C.
    The Boil Test—Strategies for Resistance Determination of Microorganisms. PDA J. Pharm. Sci. Technol. 2018, 72 (6), 566–573.
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    1. Agalloco J. P.
    Increasing Patient Safety by Closing the Sterile Production Gap—Part 1. Introduction. PDA J. Pharm. Sci. Technol. 2017, 71 (4), 261–268.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    1. Agalloco J. P.
    Increasing Patient Safety by Closing the Sterile Production Gap—Part 2. Implementation. PDA J. Pharm. Sci. Technol. 2017, 71 (4), 269–273.
    OpenUrlAbstract/FREE Full Text
  59. 59.↵
    1. Agalloco J. P.
    Increasing Patient Safety by Closing the Sterile Production Gap—Part 3. Moist Heat Resistance of Bioburden. PDA J. Pharm. Sci. Technol. 2017, 71 (4), 274–278.
    OpenUrlAbstract/FREE Full Text
  60. 60.↵
    International Organization for Standardization, ISO 15882:2008/(R)2013. Sterilization of Health Care Products—Chemical Indicators—Guidance for Selection, Use and Interpretation of Result. ISO: Geneva, 2013.
  61. 61.↵
    1. Sutton S.
    Bioburden Contamination Control: A Holistic Overview. Am. Pharm. Rev 2015, 18 (5), 1–5.
    OpenUrl
  62. 62.↵
    1. Sandle T.,
    2. Tidswell E. C.
    1. Tidswell E. C.
    Bioburden Control. In Aseptic and Sterile Processing: Control, Compliance, and Future Trends; Sandle T., Tidswell E. C., Eds.; DHI Publishing: River Grove, IL, 2017; pp 163–192.
  63. 63.↵
    ICH Quality Guideline Q10: Pharmaceutical Quality System. ICH Web site. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf (accessed February 16, 2022).
  64. 64.↵
    ICH Quality Guideline Q11: Development and Manufacture of Drug Substance (Chemical Entities and Biotechnological/Biological Entities). ICH Web site. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q11/Q11_Step_4.pdf (accessed February 16, 2022).
  65. 65.↵
    ICH Quality Guideline Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management (Draft). ICH Web site. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q12/Q12_Draft_Guideline_Step2_2017_1116.pdf (accessed February 16, 2022).
  66. 66.↵
    1. Stauffer R.
    Science Driving New State-of-the-Art Practices for Microbial Control. PDA Lett. 2015, (LI (8), 20–37.
Back to top

In This Issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Sterility Assurance—Current and Future State
Edward C. Tidswell, James P. Agalloco, Radha Tirumalai
PDA Journal of Pharmaceutical Science and Technology May 2022, 76 (3) 263-277; DOI: 10.5731/pdajpst.2020.012526
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords